Aguilera-Diaz and colleagues evaluate the performance of four different targeted NGS gene panels, three commercial panels and one in-house developed panel, and noted that CEBPA, CALR and FLT3 genes remain challenging the use of NGS for diagnosis of myeloid neoplasms in compliance with current guidelines [21]. This evidence concerns the gene CEBPA and myeloid neoplasm.